Form 8-K - Current report:
SEC Accession No. 0000950170-24-140446
Filing Date
2024-12-26
Accepted
2024-12-26 16:39:52
Documents
12
Period of Report
2024-12-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K virx-20241218.htm   iXBRL 8-K 47981
2 EX-99.1 virx-ex99_1.htm EX-99.1 13459
  Complete submission text file 0000950170-24-140446.txt   173236

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20241218.xsd EX-101.SCH 23863
15 EXTRACTED XBRL INSTANCE DOCUMENT virx-20241218_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

EIN.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 241581471
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)